Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,013 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y, Kanemasa Y, Ohigashi A, Morita Y, Tamura T, Nakamura S, Otsuka Y, Kishida Y, Kageyama A, Shimizuguchi T, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Omuro Y, Shimoyama T. Yagi Y, et al. Medicine (Baltimore). 2021 Nov 5;100(44):e27733. doi: 10.1097/MD.0000000000027733. Medicine (Baltimore). 2021. PMID: 34871273 Free PMC article.
[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y, Kanemasa Y, Sasaki Y, Hayashi Y, Mino M, Kato C, Sakai S, Ohigashi A, Kanbara Y, Morita Y, Tamura T, Atsuta Y, Konuma R, Nakamura S, Wada A, Okuya T, Kageyama A, Murakami D, Nakashima S, Uchibori Y, Onai D, Hamamura A, Nishijima A, Omuro Y, Shingai N, Shimizuguchi T, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Ohashi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Rinsho Ketsueki. 2022;63(10):1363-1372. doi: 10.11406/rinketsu.63.1363. Rinsho Ketsueki. 2022. PMID: 36351641 Japanese.
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y, Yagi Y, Kanemasa Y, Sasaki Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Ohashi K, Shimoyama T. Morita Y, et al. Among authors: yagi y. Rinsho Ketsueki. 2023;64(7):586-595. doi: 10.11406/rinketsu.64.586. Rinsho Ketsueki. 2023. PMID: 37544717 Japanese.
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Cancer Med. 2023 Sep;12(17):17808-17821. doi: 10.1002/cam4.6412. Epub 2023 Aug 28. Cancer Med. 2023. PMID: 37635630 Free PMC article.
Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.
Yagi Y, Kanemasa Y, Sasaki Y, Goto S, Yamamura Y, Masuda Y, Fujita K, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Matsuda S, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. J Clin Exp Hematop. 2024;64(2):107-118. doi: 10.3960/jslrt.24009. J Clin Exp Hematop. 2024. PMID: 38925972 Free PMC article.
1,013 results